



January 6, 2025

NEWS RELEASE

Company name: TMS Co., Ltd.
Name of representative: Takuro Wakabayashi, Chief Executive Officer
(Securities code 4891; Growth Market)

TMS to Host an Executive Roundtable at WuXi Global Forum 2025 in San Francisco

TMS Co., Ltd. (TSE: 4891) (the "Company"), a clinical-stage biopharmaceutical company focused on discovering and accelerating the development of transformative medicines in areas of high unmet medical need, today announced that Takuro Wakabayashi, Chief Executive Officer, and Reiko Namikawa, MD, Ph.D, TMS Board Member, will be hosting an executive roundtable at the WuXi Global Forum 2025 on Tuesday, January 14, 2025 at 3:45pm PT in San Francisco.

Details of Presentation at WuXi Global Forum:

Event	WuXi Global Forum 2025
Date	Tuesday, January 14, 2025
Location	Hilton San Francisco Union Square Continental Ballroom 4-6, Ballroom Level of Tower 3 333 O'Farrell Street, San Francisco, CA 94102
Session	Executive Roundtable Session II 3:45pm - 4:45pm PT
Topic	Acute-Phase Therapeutics: A Critical and Overlooked Unmet Medical Need
Participants	Takuro Wakabayashi (CEO) and Reiko Namikawa, MD, Ph.D (Board Member)
Link	Forum URL: https://wxpress.wuxiapptec.com/detail/927/WuXi-Global-Forum-2025 Link to intro video: https://wxpress.wuxiapptec.com/ExecutiveRoundtables.html

About TMS Co., Ltd.

TMS Co., Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative medicines for the treatment of serious diseases in areas of high unmet medical need. The Company's pipeline consists of a family of small molecule compounds called SMTPs (Stachybotrys Microspora Triprenyl Phenols) derived from a fungus. TMS' lead program, TMS-007 (JX10), has demonstrated efficacy and safety in its Phase 2a study for the treatment of acute ischemic stroke. The Company's robust pipeline also includes programs in resistant or uncontrolled hypertension, acute kidney injury, and spinal cord injury. TMS continues to explore new pipeline products by leveraging its established partnerships with leading academic institutions in Japan, with the intention to build a bridge between academic discoveries and the global pharmaceutical market. For more information about TMS, please visit <https://www.tms-japan.co.jp/en/>

Investor and Media Contact:

ir@tms-japan.co.jp

Kevin Lui

Precision AQ

Kevin.Lui@precisionaq.com

End